Kornimate/medical-research-clean huggingface dataset:
supermicrosurgical lva for lymphedema treatment

Conditions: Lymphedema

Summary: lva orientations such as lymphaticovenous end-to-end (lveea), end-to-side (lvesa), and side-to-end (lvsea) are commonly performed. each orientation has its own advantages and disadvantages. the key factors affecting the type of anastomotic orientation are the sizes of the lvs and the rvs, and the relative distance between them. most published literatures have focused on lvsea2-9, which is considered to be the most efficient. with one anastomosis in lvsea, the rv is able to drain both the antegrade and retrograde lymphatic flow. nevertheless, how to determine the anastomotic orientation has remained ambiguous. in this study, we aimed to establish the basis of selecting the proper anastomotic orientation, based on the size and comparative size discrepancy between lv and rv. to the best of our knowledge, this is the first report to focus on this subject.


Eligibility criteria:
inclusion criteria: * lymphedematous lower limbs (international society of lymphology stage i-iii) between march 2016 to october 2018 were included exclusion criteria: * patients whose data were missing will be excluded.
prospective evaluation of open-angle glaucoma subjects on one topical hypotensive medication treated with two istents

Conditions: Subjects With Primary Open-angle Glaucoma (POAG)

Summary: the purpose of this study is to evaluate the intraocular pressure (iop) lowering effect of two istent devices in eyes of subjects with primary open-angle glaucoma

this study evaluates the safety and efficacy of two istents implanted in primary open-angle glaucoma subjects

Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma (poag) * subject on one topical hypotensive medication exclusion criteria: * traumatic, uveitic, neovascular, or angle closure glaucoma * fellow eye already enrolled

Keywords: open angle glaucoma surgery ocular hypertension eye diseases
evaluating the initial lens handling experience of neophyte contact lens wearers fitted with precision1 and 1-day acuvue moist contact lenses

Conditions: Myopia

Summary: the initial subjecting handling experience of neophyte contact lens wearers with precision1 will be compared to that with a daily disposable lens which mas been on the market for numerous years (1-day acuvue moist).


Eligibility criteria:
inclusion criteria: 1. is between 18 and 40 years of age inclusively and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. is willing and able to follow instructions and maintain the appointment schedule; 4. is a neophyte who has no history of any previous contact lens handling experience; 5. has a refraction cyl ≤1.00dc in either eye (after vertexing to corneal plane); 6. has visual acuity ≤0.20 logmar each eye with study lenses; 7. demonstrates acceptable fit with study lenses; 8. demonstrates the ability to successfully insert and remove the study lenses 3 times for each eye (contralateral cl handling, so that each lens type inserted and removed 3x on same eye); 9. is willing to wear study cls at least 5 days per week and 6 hours per day throughout the study exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. has any known active\* ocular disease and/or infection; 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. has known sensitivity to the diagnostic pharmaceuticals to be used in the study; 6. is pregnant, lactating or planning a pregnancy at the time of enrolment (by self-report); 7. is aphakic; 8. has undergone refractive error surgery; 9. has taken part in another clinical research study within the last 14 days; 10. any ocular and/or systemic conditions or concomitant medication to contraindicate contact lens wear or be expected to interfere with the primary outcome variables. * for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
assessment and prevention of acute post-herniotomy pain

Conditions: Hernia

Summary: the aim of the study is the assessment and management of acute post-herniotomy pain using two different therapeutical protocols per os: ketorolac versus association of acetaminophene+tramadol.

persistent post-herniotomy pain (ppp) affects everyday activities in 5-10% of patients. even brief intervals of acute pain can induce long-term neuronal remodeling and sensitization, chronic pain and lasting psychological distress. chronic pain may be caused by intense acute ppp, intraoperative nerve injury and/or ongoing inflammation or mesh response with subsequence damage to nerve structures. the aim of our study is to analyze analgesic efficacy, safety and prevention of persistent postsurgical pain of two different pharmacological strategies.

Eligibility criteria:
inclusion criteria: * males and females over 18 years, under 80 years, scheduled for elective herniotomy * classification american society of anesthesiologists (asa) i: without systemic disease * classification asa ii or iii (mild systemic disease or severe systemic disease that limits the activity without invalidity). * patients with hernia typ 2, 3a, 3b (classification nyhus (1993)) * signed informed consent exclusion criteria: * asa iii, iv * emergency surgery * recovery in intensive care unit after surgery * habitual opioid consumption * nsads allergy * cognitive or mental alterations * coagulopathy * piastrinemia \< 100.000/mm3

Keywords: herniotomy
allogeneic cell therapy for adults with hematologic malignancies

Conditions: Hematologic Diseases

Summary: this is a research study involving the treatment of leukemia or lymphoma (lymph gland cancer) in adults who have leukemia or lymphoma that is unlikely to be cured with regular anticancer drugs or radiation treatments.

this is a research study involving the treatment of leukemia or lymphoma (lymph gland cancer) in adults who have leukemia or lymphoma that is unlikely to be cured with regular anticancer drugs or radiation treatments. intensive treatment with high doses of chemotherapy followed by a bone marrow transplant (bmt) from an hla-(tissue-type) matched related donor would provide the best chance for cure of this leukemia or lymphoma. however, the success of bmt from relatives is limited in patients who are older than 50 years and/or have organ dysfunction by substantial complications due to the high dose chemotherapy related toxicity, graft-versus- host disease (gvhd), and relapse. patients eligible for this study have an hla matched sibling, but a bmt from the sibling would carry a high risk for severe side effects due to the patient's age, and/or organ dysfunction. researchers are evaluating a new treatment for adult patients with leukemia and lymphoma which involves regular dose chemotherapy and blood stem cell transplantation from an hla-matched relative, with injections of donor immune cells (a type of white blood cells) given if you later relapse. in this study, the safety and feasibility of this treatment strategy are being investigated.

Eligibility criteria:
inclusion criteria: * to be eligible as a recipient for this study, patients must have chronic myelocytic leukemia (cml) in chronic phase and be older than 60 years of age, have advanced myelodysplastic syndrome (mds) and be over 60 years of age, have chronic lymphocytic leukemia (cll) and be over 50 years of age, or have low grade lymphoma and be over 50 years of age. hla typing of the recipient's family will be used to identify potential donors. please contact study nurse for additional eligibility criteria. final eligibility will be determined by the health professionals conducting this clinical trial. exclusion criteria: * patients with an active, invasive/systemic fungal infection and patients with serologic evidence of antibodies to hiv i/ii will be excluded from participating as recipients in this study. additional exclusion factors include: patients who are pregnant or lactating, those with active central nervous system (cns) malignant disease, and patients whose life expectancy is limited by diseases other than the disease for which the transplant is being performed. please contact study nurse for additional ineligibility criteria. final eligibility will be determined by the health professionals conducting this clinical trial.

Keywords: hematologic diseases
photopill treatment in healthy volunteers

Conditions: Ulcerated Mucosa of Colon

Summary: photo-bio-stimulation by low level light therapy(lllt) has demonstrated its clinical use in chemotherapy/radiotherapy oral mucositis. unpublished study (melzer, ben-yehuda et al. uegw 2012) with the photopill (lllt) capsule treatment in mice showed a significant beneficial effect on the endoscopic severity of dss-induced colitis in mice. therefore a phase 1 trial is designed to assess the safety and feasibility of the photopill treatment in healthy volunteers.


Eligibility criteria:
inclusion criteria: * subjects who are generally healthy. * signed informed consent. exclusion criteria: * subjects with any known gi related symptoms complaints or gi diseases. * subjects with cancer or other life threatening diseases or conditions. * subjects with cardiovascular or pulmonary diseases. * pregnant women. * subjects who underwent any colon surgery. * morbid obesity (bmi \> 40). * drug abuse or alcoholism. * bed-ridden patient. * any rectal therapy. * participation in current clinical study or clinical study within 30 days prior to the study.
remineralization of molar incisor hypomineralization (mih) with a hydroxyapatite toothpaste

Conditions: Molar Incisor Hypomineralization

Summary: this study tests the remineralization of donor teeth (donormih) in situ in participants using 10% hydroxyapatite (hap) toothpaste and sodium fluoride toothpaste.

prior to each 2-week treatment phase, subjects will complete a 1-week washout period. following the washout period, the intra-oral appliance containing a donormih tooth block will be fitted to each subject by a qualified dentist. immediately after fitting of the first appliance (on day 1 of the first treatment phase), each subject will receive a soft bristled manual toothbrush for use throughout the duration of the study and a toothpaste according to the treatment phase. subjects will be instructed to brush their teeth with the appliance in the mouth, two times daily, for 3 minutes on each brushing episode, in the morning after breakfast and last thing before bed, then rinsing with 10 ml of water. over the study period, all subjects will maintain their normal dietary habits. a 7-day washout period without an appliance will follow. after completion of the second washout period, subjects will return to the clinic, and the appliance, with another mih-bearing tooth blocks mounted, will be fitted to the subject for the phase 2 treatment period. this procedure will then be repeated until the 2-week treatment phase is completed, and each subject has gone through the two arms of the study.

Eligibility criteria:
inclusion criteria: * 18-60 years of age * good general health * no known history of allergy to personal care/consumer products * minimum of 20 natural uncrowned teeth (excluding third molars) * normal salivary flow rate (stimulated and unstimulated flow of ≥0.7 ml/min and ≥0.2 ml/min respectively * able to consent * availability throughout entire study * willing to wear intra-oral appliance 24 hours per day * willing to use only assigned products for oral hygiene for duration of study exclusion criteria: * advanced periodontal disease * a medical condition that requires pre-medication prior to dental visits/procedures * impaired salivary function * orthodontic retainer(s) * too few teeth to secure the oral appliance * disease of the soft or hard oral tissues * use of drugs that can affect salivary flow * use of antibiotics one month prior to or during this study * participation in another clinical study one week prior to the start of washout period or during this study period * allergic hisotry to common toothpaste ingredients * compromised immune system (hiv, aids, immunosuppressive drug therapy)

Keywords: remineralization hydroxyapatite sodium fluoride
application of artificial intelligence algorithm based on ct imaging for muscle parameter measurement

Conditions: Deep Learning; Sarcopenia; Computed Tomography; Body Composition

Summary: to establish an artificial intelligence model for automated diagnosis of sarcopenia based on ct imaging

with the accelerating aging process, the early identification and diagnosis of sarcopenia, along with the effective prevention of its adverse outcomes, have become a focal point in medical research. however, current methods for assessing and diagnosing sarcopenia still face significant limitations, making the development of more efficient and accurate techniques for muscle mass evaluation an urgent clinical need. although ct is considered as the most promising method for assessing muscle mass, its practical application is hindered by factors such as reliance on physician expertise and time-consuming procedures, limiting its widespread clinical adoption. in light of these challenges, this study aims to develop an artificial intelligence model for fully automated muscle mass measurement based on abdominal ct imaging and to validate its application value in assisting the diagnosis of sarcopenia.

Eligibility criteria:
inclusion criteria： 1. the population undergoing bia and abdominal ct examinations; 2. can cooperate to complete human body composition analysis, grip strength measurement, 6m walking time measurement, and questionnaire survey. exclusion criteria： 1. age\<18 years old; 2. existence of abdominal wall edema; 3. history of spinal surgery or vertebral fractures, or vertebral tumor lesions; 4. history of neuromuscular disorders.
global syphilis sequencing

Conditions: Syphilis

Summary: syphilis is an important sexually transmitted infection. there has been an epidemic of syphilis amongst men who have sex with men in the united kingdom in the last decade. early infection with syphilis causes a genital ulcer followed, in the absence of treatment, by a generalised illness often accompanied by rash. studies on syphilis have been limited because it is not possible to grow syphilis outside of the body. new approaches allow the whole genetic sequence of treponema pallidum to be obtained from a swab. in this study residual dna collected as part of routine patient care of patients seen at sexual health clinics in the uk will be used for sequencing. no patient contact is involved in the study which is limited to whole genome sequencing using residual material from samples. by better understanding the genome of the t.pallidum insights will be gained in to the pathogenesis of this important sexually transmitted disease.


Eligibility criteria:
inclusion criteria: * diagnosis of syphilis exclusion criteria: * no pcr positive clinical sample
a 6-month extension study of oto-104 in meniere's disease

Conditions: Meniere's Disease

Summary: this is an open-label extension study of a single intratympanic injection of oto-104 given every 3 months for a total of 2 injections. subjects must have completed either otonomy study 104-201403 (1-year, phase 2, safety study of oto-104) or 104-201508 (phase 3 study of oto-104) in order to be eligible for this open-label extension study.


Eligibility criteria:
inclusion criteria includes, but is not limited to: * subject has completed the phase 2 oto-104 1-year safety study (104-201403) or phase 3 (104-201508) clinical study. * subject has a diagnosis of definite unilateral meniere's disease by 1995 aao-hns criteria exclusion criteria includes, but is not limited to: * subject is pregnant or lactating. * subject has a history of immunodeficiency disease. * subject has experienced an adverse reaction to intratympanic injection of steroids.
association of bone and metabolic parameters with overall survival in patients with bone metastases from adenocarcinoma lung cancer (poumos)

Conditions: Bone Metastases; Lung Cancer

Summary: mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. overall survival of these patients is poor. thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival. patients and methods poumos is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage iv). all patients have a bone biopsy with molecular status characterization of the tumor for egfr, kras, braf and alk. bone metastasis localizations are obtained by bone scintigraphy or fdg-pet/ct. whole body composition is obtained by dexa scan (hologic®). the investigators assessed also fasting blood levels of bone and metabolic biomarkers. survival analyses will be performed using a proportional hazard regression model.


Eligibility criteria:
inclusion criteria: * adults over 18 years * both gender * covered by the french national insurance * first bone metastases of adenocarcinoma lung cancer (synchronous or metachrone) exclusion criteria: - adenocarcinoma previously treated by systemic oncologic treatment (chemotherapy, targeted therapy, immunotherapy)

Keywords: lung cancer bone metastases egfr kras bone biomarkers metabolic parameters
a study to assess the safety of asp7374 in adult subjects aged 20 or older

Conditions: Influenza; Vaccine

Summary: the purpose of this study is to confirm the safety until day 29 after injection of a single dose of quadrivalent vaccine asp7374 in adult subjects aged 20 or older


Eligibility criteria:
inclusion criteria: * medically stable, as judged on the basis of history and concurrent diseases * subject understands procedure of the protocol and is willing to comply with the protocol. exclusion criteria: * scheduled to receive another vaccine during the study. * received influenza ha vaccine within 180 days prior to screening. * received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine. * diagnosis of immune deficit in the past has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome. * received one of the following medications or treatment prior to vaccination with the study vaccine: * 1. within 28 days prior to vaccination with the study vaccine 1. interferon formulation 2. drugs which affect the immune system (e.g., immunosuppressants) 3. systemic corticosteroids and inhaled corticosteroids 4. g-csf and m-csf * 2. within 84 days prior to vaccination with the study vaccine 1. human immunoglobulin products 2. blood products 3. blood transfusion * 3. within 180 days prior to vaccination with the study vaccine 1. high-dose human immunoglobulin products (≥200 mg/kg) * history of anaphylactic shock or an allergic reaction such as generalized eruption due to food or drug (including vaccines) allergies, fever ≥39.0°c within 2 days after the previous vaccination (influenza vaccine and others) * history of seizures (exclude a pyrexial attack in childhood) * history of guillain-barre syndrome or acute disseminated encephalomyelitis (adem) * body temperature of ≥37.5°c on day 1 (before vaccination) * moderate to severe acute or febrile illness (≥37.5°c) within 7 days prior to vaccination * concurrent hepatic disease (exclude fatty liver, hepatic cyst, biliary stone and gallbladder poly, which have laboratory findings only, no clinical symptoms, and not necessary to treat), or ast (got) and/or alt (gpt) of \>100 iu/l at screening on day 1 * concurrent renal disease (exclude rental cyst and calculus kidney which have laboratory findings only, no clinical symptoms, and not necessary to treat), or creatinine of \> 1.5 mg/dl at screening * concurrent respiratory disease, hematologic disease, or developmental disorders * concurrent or previous heart disease * concurrent or previous cerebrovascular disorder * concurrent malignancy or diagnosis or treatment of malignancy within 5 years before screening * diagnosis of mental disorder including schizophrenia, bipolar disorder, or major depressive disorder or cognitive impairment, or received medications for cognitive impairment * concurrent disease interfering with the evaluation of local and systemic reactions

Keywords: influenza vaccine asp7374
the impact of integrated preoperative fascia iliaca compartment block in elderly hip fracture

Conditions: Hip Fractures; Pain, Acute; Hip Fracture Surgery; Delirium in Old Age; Pain Intensity

Summary: this prospective randomized controlled study is aimed to determine the advantages of post-admission fascia iliaca compartment block (ficb) in geriatric hip fracture surgery combination with multimodal analgesia compared with no post-admission ficb. the primary outcome is incidence of delirium during hospital admission. secondary outcomes are incidence of delirium at hospital discharge, pre- and post-operative pain intensity, peri-operative complications, opioid-related side effects, post-operative complications and length of hospital stay, and morbidities and mortality (in-hospital and 30 days).

population: elderly patients age ≥ 65 years old, diagnosed with an isolated acute hip fracture within 7 days and plan to receive fast-track hip fracture. statistic analysis plan surgery within 48 hours after hospital admission. study population: elderly isolated hip fracture patients who are admitted in those 8 hospitals centers in thailand and have moderate pain or higher than moderate pain during movement since hospital admission. sample size : 210 patients per group (drop out 10%) total 420 patients statistical analysis: spss will be used for study analysis. the category variables will be present as number and percentage, and chi-square or fisher exact test will be used to compare between the groups.the continuous variables will be tested the distribution, data presentation will be mean and standard deviation (sd) for normal distribution while median and interquartile rang (iqr) for non-normal distribution. student t test or wilcoxson rank some test will be used as appropriate to test for different between the group. and p value less than 0.05 will be considered statically significance.

Eligibility criteria:
inclusion criteria: 1. patients who are aged ≥65 , \<85 years old and diagnose hip fracture in 8 hospitals 2. planed for fast-track hip surgery 3. isolated acute hip fracture 4. pain on admission during movement ≥ 4 (moderate pain) exclusion criteria: 1. refusal to participate the study 2. asa physical status \>iii 2. duration of fracture more than 7 days before admission 3. hip fracture after/at previous instrumentation 4. hip fracture causing by a traffic accident or high energy force 5. suspected pathologic fracture 6. unable to communication 7. abnormal consciousness or severe cognitive dysfunction that could not communication such as mental retardation, severe alzheimer's disease and schizophenia 8. allergy to local anesthetic drug